Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M231,160Revenue $M58,831Net Margin (%)19.0Z-Score3.4
Enterprise Value $M240,426EPS $3.7Operating Margin %20.7F-Score6
P/E(ttm))23.1Cash Flow Per Share $0Pre-tax Margin (%)22.1Higher ROA y-yY
Price/Book3.310-y EBITDA Growth Rate %-1.1Quick Ratio1.1Cash flow > EarningsY
Price/Sales4.45-y EBITDA Growth Rate %-6.2Current Ratio1.4Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %8.2ROA % (ttm)8.6Higher Current Ratio y-yY
Dividend Yield %2.8Insider Buy (3m)0ROE % (ttm)15.1Less Shares Outstanding y-yY
Payout Ratio %66.0Shares Outstanding M2,419ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with NVS

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVSLee Ainslie 2014-09-30 Buy 0.38%$85.25 - $94.8
($90.27)
$ 95.566%New holding, 272570 sh.272,570
NVSRuane Cunniff 2014-09-30 Buy $85.25 - $94.8
($90.27)
$ 95.566%New holding, 7772 sh.7,772
NVSHOTCHKIS & WILEY 2014-09-30 Reduce-0.21%$85.25 - $94.8
($90.27)
$ 95.566%Reduce -98.51%9,646
NVSPRIMECAP Management 2014-09-30 Reduce-0.16%$85.25 - $94.8
($90.27)
$ 95.566%Reduce -6.74%22,239,448
NVSDodge & Cox 2014-06-30 Add0.4%$82.51 - $90.98
($87.73)
$ 95.569%Add 10.04%51,102,219
NVSHOTCHKIS & WILEY 2014-06-30 Reduce-0.52%$82.51 - $90.98
($87.73)
$ 95.569%Reduce -71.8%649,519
NVSLee Ainslie 2014-06-30 Sold Out -0.42%$82.51 - $90.98
($87.73)
$ 95.569%Sold Out0
NVSLee Ainslie 2014-03-31 Add0.1%$78.2 - $83.82
($81.23)
$ 95.5618%Add 31.52%351,580
NVSPRIMECAP Management 2014-03-31 Reduce-0.26%$78.2 - $83.82
($81.23)
$ 95.5618%Reduce -10.13%24,014,586
NVSLee Ainslie 2013-12-31 Reduce-0.56%$72.96 - $80.39
($77.55)
$ 95.5623%Reduce -66.76%267,321
NVSChris Davis 2013-09-30 Sold Out -0.01%$70.66 - $77.08
($73.84)
$ 95.5629%Sold Out0
NVSLee Ainslie 2013-06-30 Add0.2%$68.42 - $75.5
($72.61)
$ 95.5632%Add 39.5%741,689
NVSJohn Hussman 2013-06-30 Reduce-0.52%$68.42 - $75.5
($72.61)
$ 95.5632%Reduce -47.49%218,900
NVSVanguard Health Care Fund 2013-06-30 Sold Out -0.2%$68.42 - $75.5
($72.61)
$ 95.5632%Sold Out0
NVSLee Ainslie 2013-03-31 Buy 0.49%$63.3 - $71.32
($67.87)
$ 95.5641%New holding, 531689 sh.531,689
NVSVanguard Health Care Fund 2013-03-31 Reduce-0.71%$63.3 - $71.32
($67.87)
$ 95.5641%Reduce -85.39%726,200
NVSIrving Kahn 2013-03-31 Reduce-0.1%$63.3 - $71.32
($67.87)
$ 95.5641%Reduce -21.03%33,456
NVSDodge & Cox 2012-12-31 Add0.11%$58.97 - $63.96
($61.79)
$ 95.5655%Add 2.65%48,438,459
NVSKen Fisher 2012-09-30 Buy 0.86%$55.24 - $61.51
($58.49)
$ 95.5663%New holding, 5086362 sh.5,086,362
NVSDodge & Cox 2012-09-30 Add0.12%$55.24 - $61.51
($58.49)
$ 95.5663%Add 3.23%47,187,759
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVS is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
NVS Ruane Cunniff 2014-09-307,77200New Buy
NVS Lee Ainslie 2014-09-30272,5700.010.38New Buy
NVS Irving Kahn 2014-09-3030,36800.46+15.17%
NVS Ken Fisher 2014-09-306,015,2330.251.2+0.76%
NVS John Hussman 2014-09-30214,0000.011.7
NVS Dodge & Cox 2014-09-3050,905,4492.14.6-0.39%
NVS Mario Gabelli 2014-09-3010,19000.01-0.49%
NVS Jean-Marie Eveillard 2014-09-3012,84800-1.62%
NVS Tweedy Browne 2014-09-30283,9830.010.62-1.68%
NVS PRIMECAP Management 2014-09-3022,239,4480.922.2-6.74%
NVS HOTCHKIS & WILEY 2014-09-309,64600-98.51%
Premium Most recent portfolio changes are included for Premium Members only!


NVS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Novartis Bioventures Ltd10% Owner 2014-09-22Buy325,000$15537.07view

Press Releases about NVS :

    Quarterly/Annual Reports about NVS:

      News about NVS:

      Articles On GuruFocus.com
      Kahn Brothers' Third Quarter Numbers Nov 07 2014 
      Tweedy Browne Global Reports its Top Five Picks of Q3 Oct 21 2014 
      Zoetis Will Benefit from Industry Trends Oct 07 2014 
      International Securities For A Diversified Income Portfolio Sep 23 2014 
      Widely Held Guru Stocks Trading In Europe Sep 22 2014 
      Why Investing Internationally Can Help Your Portfolio Sep 12 2014 
      Weekly 52-Week Highs Highlight: LLY, BG, NVS, HRL Sep 07 2014 
      Sarah Ketterer’s Causeway International Value Fund Reports Top Five Aug 31 2014 
      I Am Sure This Pharma-Company Suits Your Portfolio Aug 28 2014 
      A Strong Candidate for Investor´s Portfolios Aug 12 2014 


      More From Other Websites
      GSK-Novartis deal wins US trade regulator approval Nov 27 2014
      Regulatory update on transaction with Novartis Nov 27 2014
      Regulatory update on transaction with Novartis Nov 26 2014
      U.S. approves GSK's purchase of Novartis vaccine business-companies Nov 26 2014
      Novartis selling nicotine patch to win U.S. nod for GlaxoSmithKline deal - FTC Nov 26 2014
      Novartis to Divest Nicotine Patch Habitrol Nov 26 2014
      Novartis selling nicotine patch to win U.S. nod for GlaxoSmithKline deal -FTC Nov 26 2014
      Novartis selling nicotine patch to win U.S. nod for GlaxoSmithKline deal -FTC Nov 26 2014
      Novartis selling nicotine patch to win U.S. nod for GlaxoSmithKline deal -FTC Nov 26 2014
      Novartis' Multiple Myeloma Drug FDA Action Date Delayed Nov 26 2014
      1:21 am Novartis announces extension to FDA review period for multiple myeloma investigational... Nov 25 2014
      Novartis' Psoriasis Drug Cosentyx Backed for EU Approval Nov 24 2014
      Can Partnering To Fight Hepatitis C Pay At Enanta? Nov 24 2014
      Novartis Dismisses Employee who Fabricated Data in Research Papers Nov 24 2014
      GSK shareholders to vote on Novartis deal on Dec. 18 Nov 24 2014
      GSK shareholders to vote on Novartis deal on Dec. 18 Nov 24 2014
      GSK shareholders to vote on Novartis deal on Dec. 18 Nov 24 2014
      Novartis Wins European Backing for Psoriasis Drug Cosentyx Nov 21 2014
      Novartis Foundation symposium showcases sustainable healthcare interventions » Nov 21 2014
      Novartis Cosentyx(TM) receives positive CHMP opinion for first-line treatment of moderate-to-severe... Nov 21 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK